research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Treatment-resistant giant unilateral Bowen’s disease of the scalp responding to radiotherapy
Radiotherapy was effective for treating a large scalp plaque of Bowen's disease when other treatments failed.
research Comparison of Efficacy and Specificity in Cancer‐Targeting Prodrug Conjugates
The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions
Vitexin shows promise as a cancer treatment by affecting key cellular processes and pathways.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research PROTACs in 2025: from the laboratory concept to clinical breakthrough
PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Folate-cyclodextrin Conjugate for Targeted Chemotherapy
The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction
A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
research A rare case of multiple keratoacanthomas treated with oral acitretin and intralesional methotrexate
A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Platelet rich plasma intradermal injections the area of expression of CD34 and B-catenin in males with androgenetic alopecia 11th World Congress for Hair Reserch
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
research Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
research Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments.
Advanced therapy medicinal products show promise for vitiligo treatment with fewer side effects, but affordability is a challenge.
research CD44/TRPV1 dual-targeted nanocarrier enables drug retention and multidimensional therapy for inflammatory skin diseases
research The Efficacy of Intralesional Pentoxifylline Injection versus the Standard Intralesional Corticosteroid Injection in The Treatment of Alopecia Areata
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Microneedling with topical administration of bleomycin as a treatment method for plantar warts
Microneedling with bleomycin effectively treats plantar warts with fewer sessions.
research Methotrexate/tacrolimus/voriconazole
A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
research B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy
Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
research Epigenetic Regulation of Medulloblastoma Proliferation by Finasteride-Induced Modulation of BTG2 and CD244 Gene Methylation
Finasteride may help treat childhood brain tumors by activating certain genes.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.